Amanda Pacheco

Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.

Cooley advised Otsuka Pharmaceutical, a total healthcare company focused on each individual’s potential to enhance their well-being, on its global strategic collaboration with Harbour BioMed to advance BCMAxCD3 bispecific T-cell engagers for treating autoimmune diseases.

Cooley advised Philochem AG, a wholly owned subsidiary of the Philogen Group (Milan Stock Exchange: PHIL), on its definitive license agreement with RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), granting RayzeBio exclusive worldwide rights to develop, manufacture and commercialize OncoACP3, a clinical-stage therapeutic and diagnostic agent targeting prostate cancer.

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.